丽珠集团(000513) - 2023年5月投资者关系活动记录表

Financial Performance - In 2022, the company achieved a revenue of CNY 12.63 billion, a year-on-year increase of 4.69% [1] - The net profit attributable to shareholders was CNY 1.909 billion, up 7.53% year-on-year [1] - In Q1 2023, the company reported a revenue of CNY 34.13 billion, a decrease of 1.90% year-on-year, with a net profit of CNY 5.82 billion, an increase of 5.17% [2] - The revenue from chemical preparations in Q1 2023 was CNY 16.24 billion, down 20.95% year-on-year [2] Business Segments - Chemical preparations generated revenue of CNY 70 billion in 2022, a slight increase of 0.02% [1] - The raw materials and intermediates segment achieved revenue of CNY 9.96 billion, a growth of 10.64% [2] - The traditional Chinese medicine segment saw revenue of CNY 12.54 billion, up 17.07% [1] - The newly added biopharmaceutical segment generated CNY 4.08 billion, a significant increase of 80.94% [2] R&D and Innovation - The company has maintained a compound annual growth rate of over 15% in net profit for the past decade [2] - R&D investment accounts for over 10% of revenue, focusing on innovative and complex formulations [2] - The company plans to launch an average of 3-5 key formulation products annually [3] Shareholder Returns and ESG - The company has maintained a dividend yield between 3.1% and 4.9% over the past five years, with cumulative dividends of approximately CNY 7.5 billion over the last decade [3] - The company has received an AA rating in MSCI-ESG, placing it among the top 10% of global peers [3] Market Outlook and Strategies - The company is actively expanding its product pipeline through licensing, partnerships, and strategic collaborations [3] - Plans to enhance market presence in the pet medicine sector, with two products already approved and more in development [6] - The company is also focusing on the development of vaccines beyond COVID-19, with ongoing research into multi-valent vaccines [6] Investor Relations Activities - The company engaged with 86 institutions during a recent investor relations event, including major securities firms [1] - The company is committed to maintaining transparent communication with investors and has implemented share buyback programs to enhance shareholder value [5]